CD44 and neoplasm: Using anti‐CD44 monoclonal antibody, the levels of phosphorylated‐mTORC1, phosphorylated‐mTORC2 and phosphorylated‐Akt were reduced, leading to enhanced differentiation of HL60, THP‐1 and KG1a leukaemic cells and tumour growth suppression.49